Avalo Therapeutics, Inc.
Nasdaq · Healthcare · Pharmaceutical Preparations · Wayne, PA
AVTX chart
What traders are saying about $AVTX
Latest postsAvalo Therapeutics, Inc. news
- Wedbush Maintains Avalo Therapeutics(AVTX.US) With Buy Rating, Cuts Target Price to $20
富途牛牛 ·
- Avalo Therapeutics CEO to present at BTIG Biotechnology Conference
scanx.trade ·
- Wedbush maintains Avalo Therapeutics at Outperform, lowers price target to $20 from $22
TradingView ·
- Avalo Therapeutics 3Q Research and Development Expenses $15M >AVTX
Moomoo ·
- FMR holds voting rights over 474,127 shares in its reported Avalo Therapeutics (AVTX) stake.
Stock Titan ·
- Avalo Therapeutics (AVTX) Falls 6.22% to $6.63, Pulling Back Toward Key Support - Double Bottom
https://www.dars.gov.et/ ·
- Stifel cuts Avalo Therapeutics stock price target on trial data
Investing.com ·
- Avalo Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Avalo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
www.marketscreener.com ·
- Avalo Therapeutics Inc (C6K0.SG) Seasonal returns chart
Yahoo Finance UK ·
- Avalo Therapeutics Enters New $200 Million Stock Sales Agreement
TipRanks ·
- Stock sales may carry up to a 3% commission under Avalo Therapeutics (AVTX)'s Jefferies deal.
Stock Titan ·
Avalo Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $59,000 | $441,000 | $1.9M | $18.1M |
| Net income | -$78.3M | -$35.1M | -$31.5M | -$41.7M |
| Diluted EPS | $-5.84 | $-20.91 | $-113.58 | $-1063.00 |
| Total assets (year end) | $116.5M | $150.7M | $21.0M | $33.4M |
| Cash and equivalents (year end) | $15.9M | $134.5M | $7.4M | $13.2M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Avalo Therapeutics, Inc.
- Ticker
- AVTX (Nasdaq)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Wayne, PA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1534120
- Former names
- Cerecor Inc.
Frequently asked questions
What exchange is Avalo Therapeutics, Inc. listed on?
Avalo Therapeutics, Inc. trades on the Nasdaq under the ticker symbol AVTX.
What industry is Avalo Therapeutics, Inc. in?
Avalo Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Avalo Therapeutics, Inc. headquartered?
Avalo Therapeutics, Inc.'s business address on file with the SEC is in Wayne, PA.
When does Avalo Therapeutics, Inc.'s fiscal year end?
Avalo Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Avalo Therapeutics, Inc. report?
Avalo Therapeutics, Inc. reported $59,000 in revenue for calendar year 2025, according to its SEC filings.